ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

HIO Healthcare Inv

14.75
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Healthcare Inv LSE:HIO London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.75 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Collagen Solutions PLC FDA approval for NovaBone product

03/09/2015 7:00am

RNS Non-Regulatory


TIDMCOS

Collagen Solutions PLC

03 September 2015

Collagen Solutions Plc

(the "Company" or the "Group")

FDA approval for NovaBone product

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its long term client, NovaBone Products LLC (NovaBone), has had a novel device approved by the US FDA, for use in the delivery of its collagen bone graft product MacroFORM.

NovaBone has received FDA approval for the NovaBone MacroFORM MIS Delivery System designed for minimally invasive orthopedic procedures. The system was developed for surgeons requiring controlled and precise delivery of collagen bone grafting material to surgical sites that aren't readily accessible. NovaBone's MacroFORM technology allows the delivery of bone marrow aspirate and other bioactive formulations to a graft in a ready to use, minimally invasive cannula.

NovaBone has introduced six new collagen products in the last 12 months for use in the wound care and bone graft markets based on the Company's novel regenerative medicine technology and core competencies in designing innovative and cost-effective medical devices. These products use medical grade collagen supplied by Collagen Solutions plc.

Commenting on the approval Stewart White, CEO of Collagen Solutions, said: "Once again, we see the long-term value generation that we can gain by having our collagen embedded into novel products. This impressive innovation by the team at NovaBone around making their collagen products easier to use ensures a commitment to growth of these products within attractive addressable markets. It is anticipated this regulatory approval for NovaBone will have a direct effect on revenues to Collagen Solutions."

Art Wotiz, President of NovaBone Products said "We continue to reach milestones we have established. Our team has done an excellent job in terms of both design and manufacturing of collagen products and creating a robust pipeline of products that harness the natural healing process of the body."

Enquiries:

 
 Collagen Solutions Plc 
 David Evans, Chairman                  Tel: 07740 084 452 
 Stewart White, CEO                     Tel: 0141 648 9100 
 
 Panmure Gordon & Co (Nominated          Tel: 0207 8862 714 
  Advisor and Broker)                     Tel: 020 7886 2905 
  Robert Naylor (Corporate Finance) 
  Maisie Atkinson (Corporate Broking) 
 
 Walbrook PR Ltd                        Tel: 0207 9338 780 or 
                                         collagen@walbrookpr.com 
 Anna Dunphy                            Mob: 07876 741 001 
 Mike Wort                              Mob: 07900 608 002 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAENAELFSEAF

(END) Dow Jones Newswires

September 03, 2015 02:00 ET (06:00 GMT)

1 Year Healthcare Inv Chart

1 Year Healthcare Inv Chart

1 Month Healthcare Inv Chart

1 Month Healthcare Inv Chart

Your Recent History

Delayed Upgrade Clock